Short Bowel Syndrome Market
Short Bowel Syndrome Market - Global Industry Assessment & Forecast
#
Pages:
160
2022
Feb - 2022
VMR-1318
Segments Covered
By
Drug Class GLP-2, Growth Hormone, Glutamine, Others
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2022 |
| Forecast
Years:
|
2023 - 2030 |
 Historical
Years:
|
2017 - 2021 |
 Revenue
2022: |
USD 1.18 Billion |
 Revenue 2030:
|
USD 4.44 Billion |
 Revenue CAGR
(2023 - 2030): |
18.00% |
Fastest Growing Region (2023 -
2030)
|
Asia Pacific |
Largest Region (2022):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
Short Bowel Syndrome Market Segment Analysis
- Short Bowel Syndrome Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
- GLP-2
- Growth Hormone
- Glutamine
- Others
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- U.S.
- U.S. Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- U.S. Short Bowel Syndrome Market, by Drug Class
- Canada
- Canada Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- Canada Short Bowel Syndrome Market, by Drug Class
-
Mexico
- Mexico Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- Mexico Short Bowel Syndrome Market, by Drug Class
-
North America Short Bowel Syndrome Market, by Drug Class
- Europe
-
Europe Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- U. K.
- U.K. Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- U.K. Short Bowel Syndrome Market, by Drug Class
- France
- France Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- France Short Bowel Syndrome Market, by Drug Class
-
Germany
- Germany Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- Germany Short Bowel Syndrome Market, by Drug Class
-
Italy
- Italy Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- Italy Short Bowel Syndrome Market, by Drug Class
-
Spain
- Spain Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- Spain Short Bowel Syndrome Market, by Drug Class
-
Rest of Europe
- Rest of Europe Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- Rest of Europe Short Bowel Syndrome Market, by Drug Class
-
Europe Short Bowel Syndrome Market, by Drug Class
- Asia Pacific
-
Asia Pacific Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- China
- China Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- China Short Bowel Syndrome Market, by Drug Class
- Japan
- Japan Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- Japan Short Bowel Syndrome Market, by Drug Class
-
Germany
- Germany Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- Germany Short Bowel Syndrome Market, by Drug Class
-
India
- India Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- India Short Bowel Syndrome Market, by Drug Class
-
South Korea
- South Korea Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- South Korea Short Bowel Syndrome Market, by Drug Class
-
South East Asia
- South East Asia Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- South East Asia Short Bowel Syndrome Market, by Drug Class
-
Rest of Asia Pacific
- Rest of Asia Pacific Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- Rest of Asia Pacific Short Bowel Syndrome Market, by Drug Class
-
Asia Pacific Short Bowel Syndrome Market, by Drug Class
- Latin America
-
Latin America Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- Brazil
- Brazil Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- Brazil Short Bowel Syndrome Market, by Drug Class
- Argentina
- Argentina Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- Argentina Short Bowel Syndrome Market, by Drug Class
-
Rest of Latin America
- Rest of Latin America Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- Rest of Latin America Short Bowel Syndrome Market, by Drug Class
-
Latin America Short Bowel Syndrome Market, by Drug Class
- Middle East & Africa
-
Middle East & Africa Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- GCC Countries
- GCC Countries Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- GCC Countries Short Bowel Syndrome Market, by Drug Class
- South Africa
- South Africa Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- South Africa Short Bowel Syndrome Market, by Drug Class
-
Rest of Middle East & Africa
- Rest of Middle East & Africa Short Bowel Syndrome Market, by Drug Class
- GLP-2
- Growth Hormone
- Glutamine
- Others
- Rest of Middle East & Africa Short Bowel Syndrome Market, by Drug Class
-
Middle East & Africa Short Bowel Syndrome Market, by Drug Class
- North America
FAQ
Frequently Asked Question
What is the global demand for Short Bowel Syndrome in terms of revenue?
-
The global Short Bowel Syndrome valued at USD 1.18 Billion in 2022 and is expected to reach USD 4.44 Billion in 2030 growing at a CAGR of 18.00%.
Which are the prominent players in the market?
-
The prominent players in the market are TAKEDA Inc (Japan), Nutrinia (Netherlands), OxThera (Sweden), VectivBio AG (Switzerland), Ardelyx (US) are the major companies operating in Short Bowel Syndrome Market..
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 18.00% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Short Bowel Syndrome include
- Rise in Prevalence of Short Bowel Syndrome
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Short Bowel Syndrome in 2022.
